Medicine and Dentistry
Breast Cancer
89%
Trastuzumab
26%
Health Care Cost
24%
Non Small Cell Lung Cancer
21%
Adjuvant Chemotherapy
20%
Malignant Neoplasm
20%
Aromatase Inhibitor
17%
Patient Referral
16%
Anthracycline
15%
Adjuvant Therapy
15%
Breast Cancer Prevention
14%
Epidermal Growth Factor Receptor 2
14%
Gamma Urogastrone
14%
Medical Oncology
13%
Hormone Therapy
12%
Clinical Trial
10%
Disease
9%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
8%
Gene Amplification
8%
Consultation
8%
Cardiotoxicity
7%
Breast Screening
7%
Pertuzumab
7%
Metastatic Breast Cancer
7%
Fluorescence in Situ Hybridization
7%
Hematological Cancer
7%
Breast Carcinoma
7%
Recurrent Disease
7%
Systematic Review
7%
Meta-Analysis
7%
Cancer Research
7%
Neoplasm
7%
Aerobic Exercise
7%
Exercise
7%
Odds Ratio
7%
Heart Left Ventricle Ejection Fraction
7%
Clinical Oncology
7%
Pathologist
7%
Mammography
7%
Cancer Diagnosis
7%
Upregulation
7%
Nurse
7%
Zoledronic Acid
7%
Aromatase
7%
Cancer Cell
7%
Primary Prevention
5%
Metastatic Carcinoma
5%
Radiation Therapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Chemotherapy
50%
Trastuzumab
47%
Cyclophosphamide
21%
Docetaxel
21%
Disease
20%
Recurrent Disease
16%
Endocrine Therapy
16%
Tamoxifen
16%
Doxorubicin
14%
Exemestane
14%
Anastrozole
14%
Aromatase Inhibitor
14%
Epirubicin
14%
Clinical Trial
13%
Anthracycline
9%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
8%
Metastatic Breast Cancer
8%
Gamma Urogastrone
7%
Neoplasm
7%
Cancer Recurrence
7%
Overall Survival
7%
Pertuzumab
7%
Non Small Cell Lung Cancer
7%
Bevacizumab
7%
Trastuzumab Emtansine
7%
Skin Lupus Erythematosus
7%
Letrozole
7%
Survivin
7%
Solid Malignant Neoplasm
7%
Epidermal Growth Factor Receptor 2
7%
Aromatase
7%
Zoledronic Acid
7%
Monoclonal Antibody
6%
Fluorouracil
5%
Lung Cancer
5%
Metastasis
5%
Keyphrases
Breast Cancer
38%
Trastuzumab
22%
Cost-utility
21%
Adjuvant Chemotherapy
16%
Postmenopausal Women
14%
HER2-positive Metastatic Breast Cancer
14%
Neoadjuvant Endocrine Therapy
14%
Anastrozole
14%
Exemestane
14%
Women with Breast Cancer
10%
Early Breast Cancer
9%
Overall Survival
8%
Cancer Center
8%
Adjuvant Trastuzumab
8%
Breast Cancer Treatment
8%
Docetaxel
8%
Canada
7%
Cyclophosphamide
7%
Pathological Outcomes
7%
Breast Cancer Prevention
7%
Screen-detected
7%
Breast Screening Programme
7%
Relapsed Lymphoma
7%
Refractory Hodgkin Lymphoma
7%
Carmustine
7%
Anthracycline Chemotherapy
7%
Uptake Time
7%
Cancer Patients
7%
Waiting Time
7%
3D Growth
7%
Node-negative Breast Cancer
7%
Progression-free Survival
7%
21-gene Recurrence Score
7%
Sensitive Nodes
7%
Mammography
7%
Women's Views
7%
Adjuvant Trials
7%
Herceptin
7%
Well Woman Clinics
7%
Cardiac Evaluation
7%
Mammography Screening
7%
Adjuvant Therapy
7%
Adjuvant Docetaxel
7%
Cancer Modeling
7%
Downstream Effects
7%
Cost-effective Treatment
7%
Survival Length
7%
Doxorubicin
7%
Beyond Progression
7%
Patient Survival
7%